Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2022
April 2022, Vol 13, No 2
April 2022, Vol 13, No 2
Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma
FDA Approvals, News & Updates
April 2022, Vol 13, No 2
On
March 18, 2022
, the FDA approved the combination of 2 distinct immune checkpoint inhibitors, the new LAG-3 antibody relatlimab-rmbw (Opdualag; Bristol Myers Squibb) plus the PD-1 inhibitor nivolumab (Opdivo; Bristol Myers Squibb), for patients aged ≥12 years with unresectable or metastatic melanoma.
Read More
Survey of Oncologists Identifies Several Misconceptions Regarding Biosimilars
By
Chase Doyle
Biosimilars
April 2022, Vol 13, No 2
Adoption of biosimilars continues to rise in the United States, but oncologists’ knowledge regarding these agents has not kept pace, according to data presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Quality Care Symposium.
Read More
Analysis of Insurance Claims Reveals Upward Trend in the Use of Trastuzumab Biosimilars
By
Chase Doyle
Biosimilars
April 2022, Vol 13, No 2
The development of biosimilar medicines has provided an opportunity for patient utilization of oncology treatments at a lower cost, particularly in individuals for whom biologicals play a predominant role in providing effective therapeutic and supportive care.
Read More
Elacestrant Yields Positive Outcomes in Patients with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
By
Phoebe Starr
Breast Cancer
April 2022, Vol 13, No 2
The investigational oral selective estrogen receptor degrader (SERD) elacestrant (RAD1901) significantly reduced the risk for death or disease progression and improved progression-free survival (PFS) compared with standard-of-care (SOC) endocrine therapy in patients with estrogen receptor (ER)-positive,
HER2
-negative metastatic breast cancer who had progressed on previous endocrine and targeted therapies, according to results of the phase 3 EMERALD clinical trial.
Read More
The International Cholangiocarcinoma Research Network Program Initiatives
Cholangiocarcinoma
April 2022, Vol 13, No 2
The International Cholangiocarcinoma Research Network (ICRN) is a program initiated by the Cholangiocarcinoma Foundation (CCF).
Read More
Study Finds 1 in 6 Patients with Cancer Experience “Long-Haul” COVID-19
By
Phoebe Starr
COVID-19 & Cancer
April 2022, Vol 13, No 2
According to data from a European registry, approximately 1 in 6 patients with cancer who recovered from COVID-19 infection experienced long-term sequelae (ie, “long-haul” COVID-19), placing them at increased risk for death or discontinuation of anticancer treatment.
Read More
Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker
FDA Approvals, News & Updates
April 2022, Vol 13, No 2
On
March 21, 2022
, the FDA approved a new indication for the PD-1 inhibitor pembrolizumab (Keytruda; Merck) as monotherapy for advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test, in patients whose disease progressed after previous systemic therapy in any setting and who are not candidates for curative surgery or radiation.
Read More
Opdivo plus Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
FDA Approvals, News & Updates
April 2022, Vol 13, No 2
On
March 4, 2022
, the FDA accelerated the approval of the PD-1 inhibitor nivolumab (Opdivo; Bristol Myers Squibb) in combination with platinum-doublet chemotherapy for the neoadjuvant treatment of adults with resectable non–small-cell lung cancer (NSCLC). This represents the first FDA approval for neoadjuvant therapy for early-stage NSCLC.
Read More
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer
FDA Approvals, News & Updates
April 2022, Vol 13, No 2
On
March 11, 2022
, the FDA accelerated the approval of the oral PARP inhibitor olaparib (Lynparza; AstraZeneca) for the adjuvant treatment of adults with
HER2
-negative, high-risk early breast cancer and deleterious or suspected deleterious germline
BRCA
mutation after neoadjuvant or adjuvant chemotherapy. Patients must be selected for olaparib therapy for this indication based on an FDA-approved test.
Read More
Updated Results from KEYNOTE-564 Trial Confirm Benefit of Adjuvant Pembrolizumab in Patients with Renal-Cell Carcinoma at High Risk for Recurrence
By
Phoebe Starr
ASCO GU 2022 Highlights
April 2022, Vol 13, No 2
Adjuvant pembrolizumab (Keytruda) continued to provide a disease-free survival (DFS) benefit in patients with renal-cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy, according to 30-month follow-up data from the KEYNOTE-564 trial presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.
Read More
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma